Clinical Trial Update: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases [Phase 3]

View source ↗

Summary

A Phase 3 bioequivalence study comparing Gammaplex 10% and Gammaplex 5% intravenous immunoglobulin in patients with primary immunodeficiency diseases, reporting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency
• Hyper-igm Syndrome
• Immunodeficiency Diseases
• X-linked Agammaglobulinemia

Drugs mentioned

• Gammaplex 10% (Immune globulin, human)
• Gammaplex 5% (Immune globulin, human)

Snippet

Sponsor: Bio Products Laboratory | Conditions: Primary Immune Deficiency Disorders, Common Variable Immunodeficiency | Phase 3 | Status: COMPLETED | Results posted: 2017-03-29